What is the appropriate next step in management for a 25‑year‑old woman with atypical squamous cells of undetermined significance on Pap and high‑risk HPV positive (E6/E7 oncogene expression)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of 25-Year-Old Woman with ASC-US and HPV E6/E7 Positive

This patient requires immediate colposcopy with directed biopsy. The combination of ASC-US cytology with positive high-risk HPV E6/E7 oncogene expression significantly elevates her risk of underlying high-grade cervical intraepithelial neoplasia (CIN 2+), warranting direct colposcopic evaluation rather than surveillance. 1, 2

Rationale for Immediate Colposcopy

  • Women aged ≥25 years with ASC-US and positive high-risk HPV testing should undergo immediate colposcopy, as this combination carries approximately 9.7% risk of CIN 2+ and up to 20% risk in some studies. 3, 1, 2

  • HPV E6/E7 oncogene expression is particularly concerning because it indicates active viral transcription and represents a truly dangerous position with higher progression risk compared to HPV DNA positivity alone. 4, 5

  • The American Society for Colposcopy and Cervical Pathology (ASCCP) specifically recommends HPV testing for triaging women >25 years of age with ASC-US, and when positive, immediate colposcopy is indicated. 3

  • HPV-positive ASC-US carries an 18% 5-year risk of histologic HSIL and cancer, compared to only 1.1% for HPV-negative ASC-US, making immediate evaluation critical. 6

Colposcopy Procedure Details

  • Perform colposcopy with directed biopsy of any visible lesions suspicious for CIN 2 or higher-grade disease. 1, 2

  • Endocervical sampling is preferred when no lesions are identified on colposcopy and in cases of unsatisfactory colposcopy. 2

  • If colposcopy identifies CIN 2+, proceed with appropriate treatment (ablative therapy or excisional procedure) according to standard protocols. 1, 2

Post-Colposcopy Management

  • If colposcopy shows only CIN 1 or is negative, follow-up options include:

    • Preferred: HPV DNA testing at 12 months 2
    • Alternative: Repeat cytology at 6-month and 12-month intervals until two consecutive negative results are obtained 3, 2
  • If HPV remains positive or cytology progresses to ASC-US or higher-grade abnormality at follow-up, repeat colposcopy is indicated. 2

Why Not Alternative Management Strategies

  • Repeat cytology alone is inadequate for this patient because it has significantly lower sensitivity (73.7%) compared to HPV-guided triage and would result in a 39% colposcopy referral rate versus the more efficient HPV-directed approach. 7

  • Observation with routine screening is inappropriate because HPV-positive ASC-US in a 25-year-old woman represents a significantly elevated risk that requires active evaluation, not passive surveillance. 1, 6

  • The 2018 guidelines explicitly state that high-risk HPV testing is recommended for triaging women >25 years of age with ASC-US, and positive results warrant colposcopy. 3

Critical Pitfalls to Avoid

  • Never delay colposcopy in HPV-positive ASC-US cases, as this increases the risk of missed high-grade disease and delayed cancer diagnosis. 1, 6

  • Do not rely on repeat cytology alone for HPV-positive ASC-US, as it has lower sensitivity (76.2%) compared to immediate colposcopy. 1

  • Do not assume low risk despite ASC-US being a relatively mild cytologic abnormality; the combination with HPV positivity (especially E6/E7 expression) significantly increases risk. 1, 4, 5

  • Do not perform HPV genotyping before colposcopy in this patient who is already HPV-positive, as colposcopy is indicated regardless of specific HPV type. 1

Special Considerations for E6/E7 Testing

  • E6/E7 mRNA positivity indicates active oncogene transcription and represents a more specific marker of disease progression than HPV DNA alone, with 88.89% sensitivity and 97.53% specificity for detecting cervical lesions. 5

  • Studies show that positive HPV E6/E7 mRNA results confer a 3.08-fold higher risk of progressing to CIN 2+ within 2 years compared to negative results. 4

  • This patient's E6/E7 positivity suggests her cervical lesion is in an actively progressing state, further supporting the need for immediate colposcopic evaluation rather than observation. 4

References

Guideline

Management of Abnormal Cervical Screening Results

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of ASC-US with Positive HPV

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Atypical Squamous Cells on Pap Smear

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.